Skip to content Skip to footer
Subscribe Now
PharmaShots' Key Highlights of Second Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 2022

Read more

Exclusive_Anita Holz1_Alanna Morris2-2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Anita Holz of Boehringer Ingelheim And Alanna Morris of Emory University Share Insight on Hear Your Heart

In an interview with PharmaShots, Anita Holz, MSN, CRNP, Therapeutic Area Head, Cardiometabolism Medical Affairs, Boehringer Ingelheim & Alanna Morris, Associate Professor of Medicine, Division of Cardiology, Emory University School of Medicine shared their views on the launch of Hear Your Heart to provide resources and education for women with heart failure & highlight inequitable care in black and Latina women Shots: Boehringer &…
May 16, 2022

Read more

Biopharma Deal Terminations Top 20 2021
TOP 20

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Shots: The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination. SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…
March 10, 2022

Read more

Insights+ Key Biosimilars Events of April 2021
INSIGHTS+

Insights+ Key Biosimilars Events of April 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC's approval for…
May 6, 2021

Read more

Biopharma Deal Terminations Top 20 2020
TOP 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…
February 11, 2021

Read more

Load more